About this episode

Scott Galloway interviews David Ricks about the challenges facing America's healthcare system and the future of obesity treatment.

David Ricks, Chair and CEO of Eli Lilly, joins Scott to discuss the rise of GLP-1 drugs, the future of obesity treatment, and why America's healthcare system is facing a crisis of trust. They explore healthcare costs, addiction, unregulated peptides, pharmaceutical innovation, and the role AI could play in the next generation of drug discovery. Want to listen to this and other episodes ad-free? You can, if you subscribe at profgmedia.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices

People in this episode

Host: Scott Galloway

Guest: David Ricks

Topics covered

• healthcare
• GLP-1 drugs
• obesity treatment
• healthcare costs
• pharmaceutical innovation
• AI in drug discovery

Keywords

• healthcare crisis
• GLP-1
• obesity
• pharmaceuticals
• AI
• drug discovery
• healthcare costs

Mentioned in this episode

Organizations: Eli Lilly

More episodes of The Prof G Pod with Scott Galloway

• No Mercy / No Malice: Optimization · June 6, 2026 · 16 min
• The Week: AI, GLP-1s, and Scott's Iran War Reversal · June 5, 2026 · 21 min
• Is Energy the Next Big Trade? + How to Actually Tax Billionaires · June 3, 2026 · 25 min
• China Decode: Can China Challenge Nvidia’s Dominance? · June 2, 2026 · 46 min

Explore listener stats, chart rankings, contacts and more on the The Prof G Pod with Scott Galloway podcast page.